Skip to main content

SpaceXAI Adopts NVIDIA Vera CPU to Accelerate Agentic AI at Massive Scale

SpaceXAI Scales NVIDIA Vera Rubin From Terrestrial AI Factories to First-Generation Starmind SatelliteNVIDIA Vera CPUSpaceXAI will deploy NVIDIA Vera CPUs to accelerate the work behind its next generation of agentic AI workloads.News Summary:SpaceXAI will deploy NVIDIA Vera CPUs to accelerate the work behind its next generation of agentic AI workloads. SpaceXAI is expanding its AI infrastructure for Grok with the NVIDIA Vera Rubin platform as it scales toward gigawatts of computing capacity. SpaceXAI plans to extend its use of NVIDIA accelerated computing into space, with the first-generation Starmind AI satellite based on an optimized NVIDIA Vera Rubin NVL72 system.SANTA CLARA, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) — NVIDIA today announced that SpaceXAI will deploy NVIDIA Vera CPUs to accelerate its next generation...

Continue reading

NVIDIA Groq 3 LPX Now in Full Production With World-Class Speed for Agentic AI

Groq 3 LPX Extends the Vera Rubin Platform, Delivering Ultrafast Token Generation for the Next Generation of Agentic AI, With Nebius the First to AdoptNVIDIA Groq 3 LPXNVIDIA Groq 3 LPX, the interactive AI inference accelerator, is now in full production.News Summary:In Artificial Analysis benchmarking, Groq 3 LPX showcased world-class speed for agentic coding and other latency-sensitive workloads. NVIDIA Groq 3 LPX extends the inference performance of NVIDIA Vera Rubin NVL72 systems by dramatically increasing token generation rates. Nebius is the first AI cloud to adopt NVIDIA Groq 3 LPX.PALO ALTO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) — Hot Chips—NVIDIA today announced that NVIDIA Groq 3 LPX, the interactive AI inference accelerator, is now in full production. An extension of the NVIDIA Vera Rubin platform, Groq...

Continue reading

Paychex Expands Award-Winning Lifestyle Benefits to 2M+ Employees on the Paycor® Platform

Paychex extends its trusted benefits platform, used by more than 400,000 employees, to help Paycor clients attract and retain talentNew to Paycor clients, Paycor Perks brings employees more than 20 voluntary benefit options at no cost to the employer Paychex scales its successful benefits platform through Paycor Perks to help employers attract and retain talent Reinforces Paychex’s commitment to advancing employee financial wellness and overall well-being across its client baseROCHESTER, N.Y., Aug. 24, 2026 (GLOBE NEWSWIRE) — Paychex (Nasdaq: PAYX), a leading provider of expert-enabled HR, payroll, and benefits, today announced that the company is expanding its comprehensive lifestyle benefits to Paycor clients and their employees with the launch of Paycor Perks. Now fully integrated within the Paycor HCM platform, Paycor Perks...

Continue reading

Announcement of the net asset value of INVL Technology as of 30 June 2026

As provided in Section XI ‘Calculation of the Net Asset Value’ of the Articles of Association of INVL Technology, the net asset value of the Company was EUR 66,106,720 or EUR 5.5188 per share on 30 June 2026. The person authorized to provide additional information:Kazimieras TonkūnasINVL Technology Managing PartnerE-mail k.tonkunas@invltechnology.lt

Continue reading

INVL Technology results for 6 months of 2026

Equity of the Company and the Company’s net asset value as of 30 June 2026 was EUR 66.1 million or EUR 5.52 per share. At the end of 2025, these figures were EUR 64.6 million and EUR 5.4 respectively. Investments of the Company into managed companies amounted to EUR 70.2 million at the end of June 2026 and EUR 54.15 million at the end of June 2025. The net profit of the Company for 6 months of 2026 was EUR 1.51 million, the net profit of the Company for 6 months of 2025 amounted to EUR 0. 766 million. Additional information: INVL Technology, a company that invests in IT businesses, earned an unaudited net profit of EUR 1.51 million in the first half of 2026, a 97% increase from the EUR 0.766 million profit in the same period last year.  The company’s equity and net asset value (NAV) stood at EUR 66.1 million at the end of June...

Continue reading

Barfresh Re-Engages with Nation’s Fourth-Largest School District, Fueled by New In-House Manufacturing Capacity

Carton Smoothies Added to the Menu as Expanded Arps Dairy Facility Comes Online Florida’s Largest School District Adds New Product for the 2026-27 School Year LOS ANGELES, Aug. 24, 2026 (GLOBE NEWSWIRE) — Barfresh Food Group Inc. (the “Company” or “Barfresh”) (Nasdaq: BRFH), a provider of frozen, ready-to-blend and ready-to-drink beverages, today announced it has expanded its product offering with the fourth largest school district in the United States, located in Florida, to include carton smoothies on the district’s school menu beginning with the 2026-27 school year. Barfresh had previously served this Florida district, which enrolls more than 300,000 students. For a period, the Company’s ability to fully support the district’s volume was constrained by its reliance on third-party co-manufacturers, whose capacity and supply...

Continue reading

Ekoscan Integrity Group to Acquire Carestream’s U.S.-Based NDT Digital Business

With computed and digital radiography joining ultrasound and eddy current, EIG and its subsidiaries offer every major NDT technology, advising by application and bringing the right method to every inspection.Ekoscan Integrity GroupEkoscan Integrity Group to Acquire Carestream’s U.S.-Based NDT Digital BusinessChâtenoy-le-Royal, France / Rochester, N.Y., USA, Aug. 24, 2026 (GLOBE NEWSWIRE) — Ekoscan Integrity Group (EIG), a global leader advancing technologies for non-destructive testing and repair, and Carestream Health, Inc. today announced that they have signed a definitive agreement under which EIG will acquire Carestream’s US-based NDT Digital business, spanning computed radiography (CR) and digital radiography (DR). The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions. Carestream’s...

Continue reading

InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026. InnoCare delivered robust revenue growth and strengthened profitability in the first half of 2026, driven by strong commercial execution and global business development collaborations. In the first half of 2026, the Company’s revenue grew by 55.5% year-on-year to RMB 1.1 billion, and profit reached RMB 239.7 million, a turnaround from a loss in the same period last year. These results reflect the successful implementation of the Company’s strategy driven by innovation, commercialization and globalization. In the first half of 2026, InnoCare continued to accelerate innovation,...

Continue reading

Apollo Group`s interim condensed consolidated financial statements for the 3 months of 2026/2027 (unaudited)

Key Developments During the first three months of the 2026/2027 financial year, the economic environment across the Group’s operating markets remained mixed and generally challenging, particularly in Estonia and Finland. Consumer confidence remained subdued and unemployment elevated, continuing to constrain household spending. At the same time, moderating inflation and gradual growth in real incomes provided some early signs of improvement in consumer purchasing power, although the recovery in consumption remained modest. The Baltic markets showed somewhat more resilient economic dynamics, while the recovery in Finland remained slower. Despite the challenging environment, the Group continues to view the current market conditions as an attractive opportunity to expand its operations, gain market share and further strengthen its leading...

Continue reading

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication – SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026 to November 22, 2026. As part of its ongoing discussions with the FDA following the July 2026 Advisory Committee meeting, Capricor submitted an amendment to the BLA that includes 24-month...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.